Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Allogene Therapeutics, Inc.
  6. News
  7. Summary
    ALLO   US0197701065

ALLOGENE THERAPEUTICS, INC.

(ALLO)
  Report
Delayed Nasdaq  -  05/20 04:00:01 pm EDT
7.480 USD   -0.93%
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Conference, May-10-2022 08:00 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Guggenheim Adjusts Price Target for Allogene Therapeutics to $35 From $40, Maintains Buy Rating

01/03/2022 | 01:07pm EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
All news about ALLOGENE THERAPEUTICS, INC.
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
GL
05/19Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Imp..
AQ
05/10TRANSCRIPT : Allogene Therapeutics, Inc. Presents at Bank of America 2022 Healthcare Confe..
CI
05/10Allogene Therapeutics Named 2022 Bay Area 'Best Place to Work' by San Francisco Busines..
AQ
05/09Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Franc..
GL
05/05Raymond James Adjusts Allogene Therapeutics' Price Target to $13 from $36, Keeps Outper..
MT
05/04TRANSCRIPT : Allogene Therapeutics, Inc., Q1 2022 Earnings Call, May 04, 2022
CI
05/04ALLOGENE THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Conditio..
AQ
05/04ALLOGENE THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/04ALLOGENE THERAPEUTICS, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
Analyst Recommendations on ALLOGENE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 0,12 M - -
Net income 2022 -366 M - -
Net cash 2022 430 M - -
P/E ratio 2022 -2,91x
Yield 2022 -
Capitalization 1 074 M 1 074 M -
EV / Sales 2022 5 455x
EV / Sales 2023 133x
Nbr of Employees 334
Free-Float 55,9%
Chart ALLOGENE THERAPEUTICS, INC.
Duration : Period :
Allogene Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLOGENE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 7,48 $
Average target price 26,81 $
Spread / Average Target 258%
EPS Revisions
Managers and Directors
David D. Chang President, Chief Executive Officer & Director
Eric Schmidt Chief Financial Officer
Arie S. Belldegrun Executive Chairman
Alison Moore Chief Technical Officer
Barbra Sasu Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
ALLOGENE THERAPEUTICS, INC.-49.87%1 074
GILEAD SCIENCES, INC.-12.08%80 075
REGENERON PHARMACEUTICALS, INC.4.69%71 235
VERTEX PHARMACEUTICALS17.76%66 136
WUXI APPTEC CO., LTD.-16.92%42 735
BIONTECH SE-36.77%39 612